Sugi Predict

Sugi Predict / Compounds / SCHEMBL2171979

SCHEMBL2171979

SCHEMBL2171979

Cc1cc(Cl)cc2c(O)ccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 4/20 0.40
▸ SLC6A2 P23975 3/20 0.40
▸ CCR1 P32246 1/20 0.39
▸ CCR5 P51681 1/20 0.39
▸ CCR8 P51685 1/20 0.39
▸ TLR8 Q9NR97 1/20 0.39
▸ CYP3A4 P08684 5/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ LMNA P02545 4/20 0.39
▸ MAPT P10636 4/20 0.39
▸ HSP90AA1 P07900 3/20 0.39
▸ MMP14 P50281 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ TP53 P04637 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ ALOX12 P18054 2/20 0.39
▸ OPRK1 P41145 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2171980 1.00 HTT (0.40) HTTSLC6A2CCR1CCR5CCR8
SCHEMBL11007450 0.81 MAPT (0.44) HTTSLC6A2CCR1CCR8CYP3A4
SCHEMBL30351236 0.81 MAPT (0.44) HTTSLC6A2CCR1CCR8CYP3A4
SCHEMBL30351059 0.79 KDM4E (0.42) HTTSLC6A2TLR8CYP3A4KDM4E
SCHEMBL30351110 0.79 KDM4E (0.43) HTTSLC6A2CYP3A4KDM4ELMNA
SCHEMBL25229833 0.79 KDM4E (0.43) HTTSLC6A2CYP3A4KDM4ELMNA
SCHEMBL18436647 0.79 KDM4E (0.42) HTTSLC6A2TLR8CYP3A4KDM4E
SCHEMBL2171048 0.79 CCR1 (0.39) HTTSLC6A2CCR1CCR5CCR8
SCHEMBL731409 0.79 HTT (0.40) HTTSLC6A2CCR1CCR5CCR8
SCHEMBL29828708 0.76 TLR8 (0.42) HTTSLC6A2CCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 — — US disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 — — EP disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 — — CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 — — WO disclosed
EP-2346830-B1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2015-05-13 — — EP disclosed
EP-2346830-B1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2015-05-13 — — EP disclosed
US-8809579-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2014-08-19 — — US disclosed
US-8436015-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2013-05-07 — — US disclosed
US-8436015-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2013-05-07 — — US disclosed
US-20110312911-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. 2011-12-22 — — US disclosed
EP-2346830-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck Sharp & Dohme Corp. (US) 2011-07-27 — — EP disclosed
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2011-07-14 — — US disclosed
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2011-07-14 — — US disclosed
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2011-07-14 — — US disclosed
WO-2010098948-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAININ SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2010-09-02 — — WO disclosed
WO-2010030722-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2010-03-18 — — WO disclosed
WO-2010030722-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2010-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GCGR, GLP1R, GPR119 HTT 2722/4885SLC6A2 1653/4885CCR1 1312/4885
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT HTT 481/4885SLC6A2 4619/4885CCR1 4426/4885
US-20110312911-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GCGR, GLP1R, GPR119 HTT 2722/4885SLC6A2 1653/4885CCR1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.